

## Prescribing information - Refer to SmPC before prescribing.

**Fluarix Tetra**▼ Influenza vaccine (inactivated, split virion). **Indication:** prophylaxis of influenza. **Dosage and administration:** *Adults and children aged ≥36 months, previously vaccinated:* 0.5 ml for i.m injection. *Children aged 36months to <9years:* not previously vaccinated, require a second 0.5ml dose at least 4 weeks after. *Children <3years:* safety and efficacy has not been established. **Side effects:** See SmPC for full details. **Very common:** irritability, myalgia, injection site pain, fatigue, **Common:** appetite loss, drowsiness, headache, gastrointestinal symptoms, arthralgia, injection site redness, induration and swelling, shivering, fever, sweating. **Serious:** Guillain Barré syndrome, acute disseminated encephalomyelitis, anaphylaxis and angioedema. **Precautions and**

**contraindications:** hypersensitivity to components including eggs. Postpone in case of febrile illness. **Pregnancy:** can be used in all stages of pregnancy and during breastfeeding. **Legal category:** POM **Presentation and Basic NHS cost:** *Fluarix Tetra* 0.5 ml pre-filled syringe. 10 = £99.40, 1=£9.94 **MA No.** PL 10592/0302. **MAH:** SmithKline Beecham Limited trading as GlaxoSmithKline UK, Stockley Park West, Uxbridge, Middlesex, UB11 1BT. **Further information is available from:** Customer Contact Centre, GlaxoSmithKline, Stockley Park West, Uxbridge, Middlesex, UB11 1BT; customercontactuk@gsk.com; Freephone: 0800 221 441. **Fluarix** is a trademark of the GlaxoSmithKline group of companies. **Date of preparation:** May 2014. UK/FLU6/0021/14

**Adverse events should be reported. Reporting forms and information can be found at [www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/yellowcard). Adverse events should also be reported to GlaxoSmithKline on 0800 221 441.**

 **Fluarix™ Tetra**▼  
Influenza Vaccine (split virion, inactivated)